Compare XGN & PCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XGN | PCF |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.9M | 116.4M |
| IPO Year | 2019 | N/A |
| Metric | XGN | PCF |
|---|---|---|
| Price | $6.01 | $6.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $13.67 | N/A |
| AVG Volume (30 Days) | ★ 295.4K | 74.8K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.90% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $63,599,000.00 | N/A |
| Revenue This Year | $21.76 | N/A |
| Revenue Next Year | $15.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.08 | N/A |
| 52 Week Low | $2.67 | $5.71 |
| 52 Week High | $12.23 | $6.96 |
| Indicator | XGN | PCF |
|---|---|---|
| Relative Strength Index (RSI) | 26.08 | 46.93 |
| Support Level | $5.84 | $6.08 |
| Resistance Level | $6.34 | $6.15 |
| Average True Range (ATR) | 0.33 | 0.05 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 10.00 | 60.48 |
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective mainly by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.